Immunocore Holdings plc Income Statement
IMCR / Health Care|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Immunocore Holdings plc reported $400M in revenue and $36M in net loss for FY2025. Revenue has grown at a 82.0% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.5%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $400.0M | $310.2M | $249.4M | $174.4M | $36.5M |
| Cost of Revenue | $5.1M | $2.7M | $1.0M | $1.1M | $0 |
| SG&A Expense | $165.4M | $155.8M | $144.5M | $123.1M | $110.8M |
| R&D Expense | $274.9M | $222.2M | $163.5M | $101.9M | $100.2M |
| Operating Income | -$45.4M | -$70.5M | -$59.6M | -$51.7M | -$174.6M |
| Interest Expense | $12.2M | $18.8M | $5.2M | $5.4M | $5.6M |
| Income Tax | $16.4M | -$1.9M | -$5.6M | $11.7M | $150.0K |
| Net Income | -$35.5M | -$51.1M | -$55.3M | -$52.5M | -$180.0M |
| EPS (Basic) | -$0.71 | -$1.02 | -$4.24 | -$1.15 | -$4.24 |
| EPS (Diluted) | -$0.71 | -$1.02 | -$4.24 | -$1.15 | -$4.24 |
| Shares Outstanding | 50.7M | 50.1M | 48.1M | 45.7M | 42.5M |
| Operating Margin | -11.3% | -22.7% | -23.9% | -29.7% | - |
| Profit Margin | -8.9% | -16.5% | -22.2% | -30.1% | - |